TT Whole Cell Lysate: sc-364195

TT Whole Cell Lysate is derived from TT cells, a human medullary thyroid carcinoma (MTC) cell line. This lysate is widely used in cancer research to investigate the molecular mechanisms underlying medullary thyroid carcinoma, a rare form of thyroid cancer arising from parafollicular C cells. TT cells exhibit characteristic mutations in the RET proto-oncogene, making the lysate valuable for studying signaling pathways involved in tumor growth, differentiation, and metastasis. Researchers utilize TT Whole Cell Lysate to analyze the expression, phosphorylation, and interactions of key proteins within the RET signaling pathway and its downstream effectors such as MAPK/ERK, PI3K/AKT, and JAK/STAT using techniques like western blotting, immunoprecipitation, and mass spectrometry. This lysate is particularly useful for examining the effects of RET activation and its impact on cellular processes like proliferation, apoptosis, and hormone secretion. Additionally, TT Whole Cell Lysate aids in exploring the molecular basis of neuroendocrine differentiation by analyzing the expression of calcitonin and other neuroendocrine markers. By comparing TT lysates with those from normal thyroid cells, scientists can identify specific molecular alterations associated with MTC, providing insights into the cellular mechanisms driving this cancer and aiding in the development of novel research strategies in cancer biology and signal transduction.

TT Whole Cell Lysate References:

1. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.  |  Cuccuru, G., et al. 2004. J Natl Cancer Inst. 96: 1006-14. PMID: 15240784
2. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells.  |  Lin, H., et al. 2007. J Biol Chem. 282: 2776-84. PMID: 17145757